Literature DB >> 18036954

Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation.

Kapil M Bhagirath1, James W Tam.   

Abstract

Protein-losing enteropathy is a well-known complication after the Fontan procedure, and unfractionated heparin therapy has been tried with some success as a potential therapy. Low-molecular weight heparin is believed to be ineffective. We now describe a case in which an adult patient with protein-losing enteropathy after Fontan palliation was successfully treated with systemic doses of low-molecular weight heparin, with complete resolution in the 24-hour fecal alpha-1 anti-trypsin level and serum albumin. The patient continues to remain in remission with this therapy. In conclusion, these findings are novel and compel us to re-evaluate our pathophysiologic understanding of this difficult condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036954     DOI: 10.1016/j.athoracsur.2007.06.064

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Evidence of Systemic Absorption of Enteral Budesonide in Patients with Fontan-Associated Protein-Losing Enteropathy.

Authors:  Richard Ogden Roberts; Michael V Di Maria; Dania Brigham; Stephanie Hsu
Journal:  Pediatr Cardiol       Date:  2019-11-09       Impact factor: 1.655

2.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: complex congenital cardiac lesions.

Authors:  Candice K Silversides; Omid Salehian; Erwin Oechslin; Markus Schwerzmann; Isabelle Vonder Muhll; Paul Khairy; Eric Horlick; Mike Landzberg; Folkert Meijboom; Carole Warnes; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

3.  Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.

Authors:  Kurt R Schumacher; Michael Cools; Bryan H Goldstein; Viktoriya Ioffe-Dahan; Karen King; Diane Gaffney; Mark W Russell
Journal:  Pediatr Cardiol       Date:  2011-06-10       Impact factor: 1.655

Review 4.  Where Is the "Optimal" Fontan Hemodynamics?

Authors:  Hideo Ohuchi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.